To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions

Metastatic Breast CancerER Positive Breast CancerHER2-negative Breast Cancer

Interventions

DIAGNOSTIC_TEST

Thymidine kinase activity

DiviTum® assay determines the enzymatic activity of TK in serum samples

Trial Locations (1)

RECRUITING

Hospital Santo Stefano, Prato